Dr. Kilian Kelly, Ph.D. - CEO, Cynata Therapeutics - iPSC-Derived, Mesenchymal Stem Cell Therapies

Send us Fan MailDr. Kilian Kelly, Ph.D. is Chief Executive Officer and Managing Director of Cynata Therapeutics ( https://cynata.com/ ), a stem cell and regenerative medicine company that is known for its proprietary Cymerus platform, for the scalable and consistent production of mesenchymal stem cell (MSC)-based therapies.Unlike traditional MSC therapies that rely on multiple donors, the Cymerus manufacturing process ensures that cells for therapeutic use can be produced in virtually limitless quantities from a single donor – making the opportunities endless and attractive from a manufacturing standpoint. The company has completed Phase I studies for Graft vs Host disease & Diabetic Foot Ulcers and have a number of Phase II, and even have a Phase III clinical trial, in progress.Dr. Kelly has over 20 years’ experience in biopharmaceutical research and development, including almost 15 years focused on the development of mesenchymal stem cell (MSC) based therapies. He joined Cynata in March 2014, initially as Vice President, Product Development, then Chief Operating Officer from May 2019, and since July 2023 has been CEO & MD. At Cynata, he has overseen all stages of the development of the Cymerus induced pluripotent stem cell (iPSC)-derived MSC technology, including the first completed clinical trial of any iPSC-derived product worldwide.Dr. Kelly previously held positions at Biota Pharmaceuticals, Mesoblast Limited, Kendle International, Amgen and AstraZeneca. Dr. Kelly holds a Masters in Pharmacy degree from the Robert Gordon University, Aberdeen, a Ph.D. in Pharmaceutical Sciences from Strathclyde University, Glasgow, and he is a Graduate of the Australian Institute of Company Directors (AICD), Melbourne. He is a member of the International Society for Cell and Gene Therapy (ISCT), the International Society for Stem Cell Research (ISSCR), the Royal Pharmaceutical Society and the AICD.Dr. Kelly also serves on the ISCT Asia-Pacific Industry Committee, the ISSCR Best Practices Working Group for the Development of PSC-Derived Therapies and the Industry Interface Committee of the Center for Commercialization of Regenerative Medicine (CCRM) Australia.#KilianKelly #CynataTherapeutics #InducedPluripotentStemCells #MesenchymalStemCells #Immunomodulation #Immunoregulation #Mesenchymoangioblasts #GraftVersusHostDisease #GVHD #MSC #iPSC #IschaemicHeartDisease #Osteoarthritis #AcuteRespiratoryDistressSyndrome #ARDS #Inflammation #Secretome #Paracrine #RegenerativeMedicine #DiabeticWounds #KidneyTransplantation #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show